A team of researchers from the California Institute of Technology recently provided the first evidence that targeted nanoparticles can be used safely and effectively in the clinic. Led by Mark Davis, a professor of chemical engineering at Caltech, the researchers demonstrated a method in which small siRNA strands are packaged into a self-assembling nanoparticle, constructed of polymers, that then delivers the siRNA strands to the tumor and turns off a critical cancer gene. The nanoparticles can be directly injected into a patient's bloodstream and then expelled through urine.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.

Sponsored by

This webinar will cover recent advances in the use of CRISPR for generating animal models and cell lines.